Metropolis Healthcare Ltd (NSE: METROPOLIS | BSE: 542650) is India’s leading diagnostic companies with a presence across emerging markets in India and Africa. Instituted in 1981, Metropolis has founded its reputation on accurate, reliable and consistent laboratory testing and reports.
Through our widespread operational network, we offer a comprehensive range of clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease. We also offer analytical and support services to clinical research organizations for their clinical research projects. During the financial year 2019, we conducted approximately 17.0 million tests from approximately 8.9 million patient visits.
We conduct our operations through our laboratory and service network. Our laboratory network consists of 125 clinical laboratories and our service network comprises 2781 patient touchpoints.
Our Global Reference Laboratory holds accreditation from the College of American Pathologists (CAP) Laboratory Accreditation Program, which is one of the main accreditation in our industry.
Metropolis Laboratories holds accreditation from CAP (College of American Pathologists, the global gold standard in Laboratory Accreditation), Kenya Accreditation Service, International Laboratory Accreditation Cooperation, Asia Pacific Laboratory Accreditation Cooperation and National Accreditation Board for Testing and Calibration Laboratories (NABL) accreditation. Majority of our clinical laboratory machines used in our operations are approved by the US FDA and/or CE.
Large Test Menu –Our test menu is one of the most comprehensive in the industry, encompassing over 4,100 tests and test profiles, including highly specialized and esoteric assays. Our test menu capabilities are in the areas of genetics, biochemistry, molecular oncology, anatomic pathology, microbiology, hematology, immunochemistry, transplant pathology; many of these technologies which Metropolis was the first to validate and introduce to the market. These tests are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.
Established brand – Well-recognized brand, delivering quality and reliable diagnostic services since 1980
Tests Performed – During the financial year 2019, we conducted approximately 17 million tests from approximately 8.9 million patient visits
Network Strength – We have widespread presence across 19 states in India across 210 cities with a leadership position in west and south India (Source: Frost & Sullivan). Outside India, we have laboratory operations in Ghana, Kenya, Zambia, Mauritius and Sri Lanka. In addition, we have also entered into agreements with third parties for collection and processing of specimens in Nepal, Nigeria, UAE and Oman.
Quality Assurance – Our GRL holds accreditation from CAP accreditation, and, 25 of our clinical laboratories hold one or more of CAP, Kenya Accreditation Service, International Laboratory Accreditation Cooperation, Asia Pacific Laboratory Accreditation Cooperation or NABL accreditation. The majority of the machines used in our clinical laboratories are approved by the US FDA and/or CE.